JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Natural history of intracranial vascular malformations: a review.

Neurosurgery 1985 March
It is difficult to assess the natural history of intracranial vascular malformations because they are varied in nature, they are frequently silent clinically, they are often treated when they are discovered, and untreated lesions are not often followed in an organized way. Capillary telangiectasias are usually occult lesions of no clinical significance. Cavernous hemangiomas may cause seizures and may bleed, but the approximate yearly risks of bleeding and of death have not been determined. Venous angiomas seldom cause symptoms, with the exception that those in the cerebellum seem to have a propensity to bleed. Intracranial dural arteriovenous malformations (AVMs) may bleed and may cause brain injury if there is insufficient outflow into a dural venous sinus. The dural AVMs that drain into the cavernous sinus have a more benign course than those that drain into the transverse or sigmoid sinus. The aneurysm of the vein of Galen presents a different clinical picture and threat to health according to whether the patient is a neonate, an infant, or an older child. The AVM of the brain encountered in the adult usually presents with hemorrhage or seizures. An unruptured AVM has approximately a 2 to 3% risk of bleeding per year, with about a 1% risk of death per year. The mortality rate of the first hemorrhage is about 10%. Among the survivors, there is about a 6% chance of rebleeding during the 1st year and then approximately a 2 to 3% risk of bleeding per year subsequently. The mortality rate associated with a second hemorrhage is about 13%, and for subsequent hemorrhages the mortality is roughly 20%.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app